Search

Your search keyword '"Verbeeck, Roger-K"' showing total 323 results
Start Over Author "Verbeeck, Roger-K"
323 results on '"Verbeeck, Roger-K"'

1. List of contributors

Author

Abraldes, Juan Gonzalez, primary, Altieri, Mario, additional, Arroyo, Vicente, additional, Attia, Dina, additional, Baiges, Anna, additional, Baik, Soon Koo, additional, Betancourt, Fabian, additional, Chadha, Ryan, additional, Chahal, Daljeet, additional, Chen, Po-Hung, additional, Desai, Moreshwar S., additional, Doycheva, Iliana, additional, Fernandez, Javier, additional, Fouad, Yasser, additional, García-Pagán, Juan Carlos, additional, Gorgis, Noelle, additional, Gurram, Harini, additional, Hernández-Gea, Virginia, additional, Iqbal, Shaz, additional, Izzy, Manhal, additional, Jo, Jennifer, additional, Kang, Seong Hee, additional, Khalifa, Rofida, additional, Koseki, Masahiro, additional, Kuwabara, Masanari, additional, Lee, Samuel S., additional, Lisman, Ton, additional, Liu, Hongqun, additional, Luo, Xuefeng, additional, Magaz, Marta, additional, Marquez, Vladimir, additional, Moreau, Richard, additional, Nicoar-Farcu, Oana, additional, Niwa, Koichiro, additional, Okada, Atsushi, additional, Pollak, P. Timothy, additional, Saito, Yuki, additional, Singu, Bonifasius S., additional, Soy, Guillem, additional, Taniguchi, Tatsunori, additional, Turon, Fanny, additional, Valérie, Paradis, additional, VanWagner, Lisa B., additional, Verbeeck, Roger K., additional, Watt, Kymberly D., additional, Wong, Florence, additional, and Wray, Christopher L., additional

Published
2023
Full Text
View/download PDF

4. The European Union

Author

Verbeeck, Roger K., Warlin, Joëlle, Crommelin, Daan J. A., Editor-in-chief, Lipper, Robert A., Editor-in-chief, and Kanfer, Isadore, editor

Published
2017
Full Text
View/download PDF

8. Plasma concentration and eGFR in preterm and term neonates receiving gentamicin or successive amikacin therapy

Author

Singu, Bonifasius S., Ndeunyema, Milka N., Ette, Ene I., Pieper, Clarissa H., Verbeeck, Roger K., Singu, Bonifasius S., Ndeunyema, Milka N., Ette, Ene I., Pieper, Clarissa H., and Verbeeck, Roger K.

Abstract

Background: Gentamicin and amikacin are aminoglycoside antibiotics which are renally excreted and known to be nephrotoxic. Estimate of glomerular filtration rate (eGFR) per body surface area is lower in neonates than in adults and exposure to these drugs could lead to more suppression in kidney function. The aim of this study was to determine maximum and minimum plasma concentrations (Cmax and Cmin), time to reach Cmin levels of gentamicin and amika-cin, and to assess eGFR in preterm and term neonates. Methods:Two groups of patients were recruited, 44 neonates receiving gentamicin (5 mg/kg/24 h) and 35 neonates receiving amikacin (15 mg/kg/24 h) by slow intravenous injection. Patients on amikacin had been on gentamicin before being switched to amikacin. Two blood samples were drawn for the determination of the maximum and minimum plasma concentration. Primary outcomes were determination of Cmax, Cmin, and the time it took to clear the aminoglycoside to a plasma concentration below the toxicity threshold (gentamicin: < 1 mcg/mL; amikacin: < 5 mcg/mL. Results: Therapeutic range for Cmax of gentamicin (15–25 mcg/mL) or amikacin (30–40 mcg/mL) was achieved in only 27.3 and 2.9% of neonates, respectively. Percentage of neonates reaching plasma concentrations below the tox-icity threshold within the 24-hour dosing interval was 72.7% for gentamicin and 97.1% for amikacin. Positive correla-tion between gentamicin clearance and postnatal age borderline statistical significance (p=0.007), while the correla-tion between amikacin clearance and postnatal age was poor and not statistically significant (r2=− 0.30, p= 0.971). Conclusion: Although eGFR decreased significantly as a function of postnatal age in neonates receiving amikacin, the majority (91.4%) of these neonates were able to clear the drug to < 5 mcg/mL within a 24-hour dosing interval. Keywords: Neonates, Kidney function, Gentamicin, Amikacin, Nephrotoxicity

Published
2023

44. Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril

Author

Verbeeck, Roger K., primary, Kanfer, Isadore, additional, Löbenberg, Raimar, additional, Abrahamsson, Bertil, additional, Cristofoletti, Rodrigo, additional, Groot, D.W., additional, Langguth, Peter, additional, Polli, James E., additional, Parr, Alan, additional, Shah, Vinod P., additional, Mehta, Mehul, additional, and Dressman, Jennifer B., additional

Published
2017
Full Text
View/download PDF

49. Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation

Author

Musuamba, Flora T, Mourad, Michel, Haufroid, Vincent, De Meyer, Martine, Capron, Arnaud, Delattre, Isabelle K, Verbeeck, Roger K, and Wallemacq, Pierre

Subjects
Graft Rejection, Bayes Theorem, Enzyme-Linked Immunosorbent Assay, Mycophenolic Acid, Kidney Transplantation, Models, Biological, Tacrolimus, Area Under Curve, Humans, Regression Analysis, Pharmacokinetics, Drug Therapy, Combination, Drug Monitoring, Chromatography, High Pressure Liquid, Immunosuppressive Agents
Abstract

To predict simultaneously the area under the concentration-time curve during one dosing interval [AUC(0,12 h)] for mycophenolic acid (MPA) and tacrolimus (TAC), when concomitantly used during the first month after transplantation, based on common blood samples.Data were from two different sources, real patient pharmacokinetic (PK) profiles from 65 renal transplant recipients and 9000 PK profiles simulated from previously published models on MPA or TAC in the first month after transplantation. Multiple linear regression (MLR) and Bayesian estimation using optimal samples were performed to predict MPA and TAC AUC(0,12 h) based on two concentrations.The following models were retained: AUC(0,12 h) = 16.5 + 4.9 × C1.5 + 6.7 × C3.5 (r(2) = 0.82, rRMSE = 9%, with simulations and r(2) = 0.66, rRMSE = 24%, with observed data) and AUC(0,12 h) = 24.3 + 5.9 × C1.5 + 12.2 × C3.5 (r(2) = 0.94, rRMSE = 12.3%, with simulations r(2) = 0.74, rRMSE = 15%, with observed data) for MPA and TAC, respectively. In addition, bayesian estimators were developed including parameter values from final models and values of concentrations at 1.5 and 3.5 h after dose. Good agreement was found between predicted and reference AUC(0,12 h) values: r(2) = 0.90, rRMSE = 13% and r(2) = 0.97, rRMSE = 5% with simulations for MPA and TAC, respectively and r(2) = 0.75, rRMSE = 11% and r(2) = 0.83, rRMSE = 7% with observed data for MPA and TAC, respectively.Statistical tools were developed for simultaneous MPA and TAC therapeutic drug monitoring. They can be incorporated in computer programs for patient dose individualization.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results